ArticleFrontiers in oncology2026
Transcriptomics, identification, and testing of manganese metabolism-related genes in cervical squamous cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical squamous cell carcinoma (CSCC) remains a leading cause of cancer-related mortality in women, and few effective prognostic biomarkers have been identified. Although manganese metabolism (MAM) has been implicated in tumorigenesis and immune regulation, its prognostic relevance in CSCC has not been systematically explored, and existing prognostic models for CSCC have largely ignored MAM-related genes. Methods: CSCC transcriptomic and clinical datasets were obtained from public databases. MAM-related differentially expressed genes (DEGs) were identified by intersecting DEGs, weighted gene coexpression network analysis key module genes, and a curated MAM gene set. Prognostic genes were screened using univariate Cox, least absolute shrinkage and selection operator, and multivariate Cox regression analyses to construct a risk model. The model's performance was assessed Results: A four-gene prognostic signature ( Conclusion: This study presents the first MAM-related prognostic signature specifically tailored to CSCC, filling a gap in existing prognostic models that did not consider the role of MAM. The four-gene risk model offers a robust tool for patient stratification, with potential implications for guiding personalized immunotherapy and targeted therapy. These findings provide a novel framework for incorporating metabolic perspectives into CSCC prognosis and warrant further clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.